There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Acceleron Pharma (XLRN) and Intellia Therapeutics (NTLA) with bullish sentiments.
Acceleron Pharma (XLRN)
In a report released today, Edward White from H.C. Wainwright maintained a Buy rating on Acceleron Pharma, with a price target of $137.00. The company’s shares closed last Tuesday at $110.96, close to its 52-week high of $112.89.
According to TipRanks.com, White is a 5-star analyst with an average return of 24.1% and a 48.3% success rate. White covers the Healthcare sector, focusing on stocks such as Spectrum Pharmaceuticals, Karyopharm Therapeutics, and TRACON Pharmaceuticals.
Acceleron Pharma has an analyst consensus of Strong Buy, with a price target consensus of $128.50, which is a 17.7% upside from current levels. In a report issued on September 24, Raymond James also maintained a Buy rating on the stock.
See today’s analyst top recommended stocks >>
Intellia Therapeutics (NTLA)
In a report released today, Geulah Livshits from Chardan Capital reiterated a Buy rating on Intellia Therapeutics, with a price target of $57.50. The company’s shares closed last Tuesday at $22.04.
According to TipRanks.com, Livshits is a 5-star analyst with an average return of 28.4% and a 65.0% success rate. Livshits covers the Healthcare sector, focusing on stocks such as Iovance Biotherapeutics, Rocket Pharmaceuticals, and Crispr Therapeutics AG.
Currently, the analyst consensus on Intellia Therapeutics is a Moderate Buy with an average price target of $37.13, implying a 75.6% upside from current levels. In a report issued on September 18, Goldman Sachs also initiated coverage with a Buy rating on the stock with a $33.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
